Intersect ENT (NSDQ:XENT) said today that it won FDA approval for a new delivery system for its Propel Mini steroid-eluting sinus implant.
The Menlo Park, Calif.-based company said the straight delivery system is designed to place the mometasone furoate-eluting Propel Mini in the ethmoid sinus behind the nasal bridge. The SDS is slated to hit the market during the third quarter, the company said. Propel Mini will still ship with the older, curved delivery system for frontal and ethmoid placement, Intersect ENT said.
“We listened to feedback from physicians offering Propel Mini to their patients, and we are pleased to deliver this new delivery system, developed specifically with ease of use and overall procedure time in mind,” president & CEO Tom West said in prepared remarks. “The straight delivery system provides physicians with another opportunity to customize treatment to achieve the best possible patient results.”
“The new straight delivery system is designed to help me accurately deploy the Propel Mini implant into the ethmoid sinus without adjustments or secondary placements,” added Dr. Arjuna Kuperan of Houston Advanced Nose & Sinus. “It is practical for placing the Propel Mini stent at the precise location where it is intended.”
